1. Home
  2. STEX vs VERU Comparison

STEX vs VERU Comparison

Compare STEX & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Streamex Corp.

STEX

Streamex Corp.

SELL

Current Price

$0.31

Market Cap

38.0M

Sector

N/A

ML Signal

SELL

Logo Veru Inc.

VERU

Veru Inc.

SELL

Current Price

$2.13

Market Cap

41.9M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
STEX
VERU
Founded
2009
1971
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
38.0M
41.9M
IPO Year
2013
1996

Fundamental Metrics

Financial Performance
Metric
STEX
VERU
Price
$0.31
$2.13
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $25.67
AVG Volume (30 Days)
★ 979.1K
133.6K
Earning Date
11-12-2026
12-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
$18,000.00
★ $16,296,958.00
Revenue This Year
N/A
N/A
Revenue Next Year
$1,314.29
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.26
$2.03
52 Week High
$4.76
$7.33

Technical Indicators

Market Signals
Indicator
STEX
VERU
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
STEX
VERU

About STEX Streamex Corp.

Streamex Corp is a vertically integrated technology and infrastructure company. The Company is a technology company with two principal lines of business: (i) Tokenized Asset Finance, focused on digital asset and real-world asset tokenization via Streamex Exchange platform, and (ii) Biomedical Technology, focused on signal processing solutions in electrophysiology. The group provides institutional-grade solutions that bring traditional commodities and assets on-chain through secure, regulated, and yield-bearing financial instruments. It is committed to delivering transparent, scalable, and compliant digital asset solutions that bridge the gap between traditional finance and blockchain-enabled markets.

About VERU Veru Inc.

Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.

Share on Social Networks: